Related Experiment Video

Updated: Oct 11, 2025

Evaluation of the Interplay Between the Complement Protein C1q and Hyaluronic Acid in Promoting Cell Adhesion
06:54

Evaluation of the Interplay Between the Complement Protein C1q and Hyaluronic Acid in Promoting Cell Adhesion

Published on: June 15, 2019

6.1K

C1q Tumor Necrosis Factor-Related Protein 1: A Promising Therapeutic Target for Atherosclerosis

Zi-Zhen Zhang1, Gang Wang2, Shan-Hui Yin3

  • 1School of Medicine, Hunan Polytechnic of Environment and Biology, Hengyang, Hunan, China.

Journal of Cardiovascular Pharmacology
|November 29, 2021
PubMed

Insights

C1q tumor necrosis factor-related protein 1 (CTRP1) accelerates atherosclerosis by increasing vascular inflammation and macrophage foam cell formation. CTRP1 shows potential as a biomarker and therapeutic target for cardiovascular diseases.

Area of Science:

  • Cardiovascular Science
  • Metabolic Disease Research
  • Molecular Biology

Background:

  • Atherosclerosis underlies major cardiovascular and cerebrovascular diseases.
  • C1q tumor necrosis factor-related protein 1 (CTRP1), an adiponectin paralog, is involved in various pathophysiological processes.
  • Elevated CTRP1 levels are observed in patients with coronary artery disease.

Purpose of the Study:

  • To review recent advances on the role of CTRP1 in atherogenesis.
  • To highlight CTRP1's potential as a biomarker for atherosclerosis.
  • To explore CTRP1 as a therapeutic target for atherosclerosis-related diseases.

Main Methods:

  • Literature review of recent studies on CTRP1 and atherosclerosis.
  • Analysis of CTRP1's mechanisms in promoting vascular inflammation.
  • Investigation of CTRP1's role in macrophage foam cell formation and endothelial dysfunction.

Main Results:

  • CTRP1 significantly promotes vascular inflammation.
  • CTRP1 accelerates macrophage foam cell formation.
  • CTRP1 contributes to endothelial barrier dysfunction, driving atherogenesis.
  • Circulating CTRP1 levels are elevated in coronary artery disease patients.

Conclusions:

  • CTRP1 plays a critical role in the development of atherosclerosis.
  • CTRP1 presents potential as a novel biomarker for atherosclerosis.
  • CTRP1 is a promising therapeutic target for atherosclerosis and related conditions.

More Related Videos

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.4K
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.5K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
257
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
63
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
281
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
163